Annual report pursuant to Section 13 and 15(d)

Acquisitions (Details)

v3.22.1
Acquisitions (Details) - USD ($)
12 Months Ended
Apr. 01, 2021
Dec. 31, 2020
Business Acquisition [Line Items]    
Total estimated fair value of consideration   $ 0
Total preliminary fair value of consideration transferred $ 6,188  
Viridian Sciences Inc. [Member]    
Business Acquisition [Line Items]    
Common shares issued 6,186  
Contingent consideration $ 2